恩帕吉菲
医学
蛋白尿
肾脏疾病
达帕格列嗪
血糖性
重症监护医学
糖尿病
人口
内科学
卡格列净
2型糖尿病
内分泌学
环境卫生
摘要
Emerging evidence underscores the potential of SGLT-2 inhibitors to benefit a wide range of CKD patients, regardless of causes and albuminuria status. Further research in this area will improve our understanding of the roles of this new class of drug in renal protection and potentially shift the paradigm of CKD management.
科研通智能强力驱动
Strongly Powered by AbleSci AI